Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency

ENGLISH
|
JAPANESE
|
CONNECT WITH US:

Jan 27, 2023 11:46 JST

Source: Eisai

Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency

TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following a standard timeline.

In the U.S., lecanemab was granted accelerated approval as a treatment for AD by the U.S. Food and Drug Administration (FDA) on January 6, 2023. On the same day, Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway based on the results from the Phase III Clarity AD confirmatory study. In Japan, Eisai submitted a marketing authorization application to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023. In China, Eisai has initiated submission of data for a BLA to the National Medical Products Administration (NMPA) of China in December 2022.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

*Protofibrils are large Aβ aggregated soluble species of 75-500 Kd.(1),(2)

(1) "Lecanemab Sweeps up Toxic AΒ Protofibrils, Catches Eyes of Trialists." ALZFORUM, ALZFORUM, 21 Nov. 2021, bit.ly/3HzXXyE.
(2) Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7(2): e32014. doi: 10.1371/journal.pone.0032014. Epub 2012 Feb 15. PMID: 22355408; PMCID: PMC3280222.

For more information, visit www.eisai.com/news/2023/news202311.html.

Source: Eisai
Sectors: BioTech

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Latest Release

Eisai

Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Mar 24, 2023 13:22 JST

Mitsubishi Corporation

Mitsubishi Corporation: PoC Launched in Portland, Oregon to Develop Smart Multifamily Apartment
Mar 24, 2023 11:02 JST

Mitsubishi Heavy Industries, Ltd.

MHI and PLN Nusantara Power to Jointly Investigate Co-Firing with Hydrogen, Ammonia and Biomass in Indonesia's Power Plants
Mar 24, 2023 10:26 JST

Mitsubishi Heavy Industries, Ltd.

MHI Thermal Systems to Launch 22 Models of Residential-use Room Air Conditioners for the Japanese Market in 2023 (Domestic sales only)
Mar 24, 2023 10:17 JST

Fujitsu Announces Start of Acceptance Period of Takeover Offer for GK Software
Mar 23, 2023 20:28 JST

Hitachi, Ltd.

The Hitachi Group has started a strategic cooperation with the leading operator of non-cash payments Polskie ePlatnosci in the development of software and IT systems
Mar 23, 2023 18:10 JST

Eisai

Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
Mar 23, 2023 13:30 JST

Fujitsu and Osaka University develop new quantum computing architecture, accelerating progress toward practical application of quantum computers
Mar 23, 2023 11:14 JST

Fujitsu named a "Nadeshiko Brand" company for promoting women's success
Mar 22, 2023 16:45 JST

Mitsubishi Motors

Mitsubishi XRT Concept to Debut at Bangkok International Motor Show 2023
Mar 21, 2023 15:00 JST

Toyota Motor Corporation

Toyota Launches the C+walk S in Japan, a New Form of Walking-Assistance Mobility
Mar 20, 2023 18:00 JST

Toyota Motor Corporation

Another record win for Ogier aboard the GR YARIS Rally1 HYBRID
Mar 20, 2023 14:41 JST

Toyota Motor Corporation

TOYOTA GAZOO Racing secures Sebring one-two
Mar 20, 2023 14:25 JST

Eisai

Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal
Mar 20, 2023 11:18 JST

Toyota Motor Corporation

Liquid Hydrogen-Powered Corolla to be Absent from Round 1 of the Super Taikyu Series at Suzuka Development to Continue for Fuji 24 Hours Race
Mar 20, 2023 09:48 JST

Mitsubishi Heavy Industries, Ltd.

Mitsubishi Heavy Industries Power IDS to Upgrade Steam Turbine Generators at Incineration Plant in Taiwan
Mar 17, 2023 22:35 JST

Fujitsu Small Research Lab program strengthens industry-academia collaboration with growing global R&D network
Mar 17, 2023 10:31 JST

Fujitsu and Ochanomizu University establish new AI ethics research lab, leveraging AI technologies to promote gender equality
Mar 17, 2023 10:13 JST

TANAKA Establishes New Overseas Subsidiary in Seoul, Korea
Mar 16, 2023 11:00 JST

TANAKA Establishes New Overseas Subsidiary in Seoul, Korea
Mar 16, 2023 11:00 JST

More Latest Release >>